

Career-portfolio

Eva Tiensuu Janson, Professor of Medicine, MD., PhD.

Professional preparations

- University Medical Degree, Uppsala University, 1988
- Doctor Medical Sciences (PhD), Department of Internal Medicine, Uppsala University, 1995-05-17, Thesis: Carcinoid tumors – Clinical aspects and the use of somatostatin analogues for diagnosis and treatment
- Associate Professor Experimental Medicine, Uppsala University, 1999
- License to practice medicine, 1994
- Board certified Endocrinology and Diabetology, 2001
- Board certified Internal Medicine, 2002

Appointments

- Dean Faculty of Medicine, Uppsala University 2014-07-01 - ongoing
- Head of department, Dept. of Medical Sciences, Uppsala University 2009-07-01 – 2014-06-30
- Professor of Medicine at the Dept. of Medical Sciences, Uppsala University, 2008 – ongoing.
- Senior lecturer in Medicine at the Dept. of Medical Sciences, Uppsala University 2004 – 2008.
- Senior consultant at the Dept. of Endocrine Oncology, Uppsala University Hospital 2002 - ongoing
- Residency in Internal Medicine and Endocrinology, Uppsala University Hospital, 1994-04-01 – 2001-12-31, interrupted 1997-09-01 – 2000-01-01.
- Forskarassistent Medical Research Council 1997-09-01 - 1999-12-31.
- Internship including one year of research, Uppsala University Hospital, 1991-01-01 – 1994-03-31.
- Work as a junior doctor combined with research time, Uppsala University Hospital, 1988-08-31 – 1990-12-31.

- Maternal leave 91-02-20 – 92-09-01 and 94-08-08 – 95-09-15.

Scientific Qualifications

Thesis

1. **Janson ET.** Carcinoid tumors - clinical aspects and the use of somatostatin analogues for characterization and treatment. (1995) Acta Univ. Ups. Comprehensive summaries of Uppsala dissertations from the faculty of medicine 551. ISBN 91-554-3537-8.

H-index 41 (web of science), H-index 43 (Google Scholar) no of citations >4700 (February 2020) search (Janson ET or Tiensuu Janson or Janson EMT)

Scientific publications

- 1 Grandér D, Öberg K, Lundqvist M-L, **Janson ET**, Eriksson B, Einhorn S. Interferon-induced. Enhancement of 2'5'-Oligoadenylate Synthetase in Mid-gut Carcinoid Tumours. *Lancet* 1990; 336: 337-40. IF 59.1
- 2 **Janson ET**, Ahlström H, Andersson T, Öberg K. Octreotide and interferon alfa, a new combination for the treatment of malignant carcinoid tumours. *Eur J Cancer*, 1992, Vol 28A, No 10:1647-1650. IF 6.7
- 3 Rönblom LE, **Janson ET**, Perers A, Öberg KE, Alm GV. Characterization of anti-interferon-alpha-antibodies appearing during recombinant interferon-alpha2a treatment. *Clin. exp. Immunol*, 1992; 89: 330-335. IF 3.7
- 4 **Janson ET**, Rönblom L, Ahlström H, Grandér D, Alm G, Einhorn S, Öberg K. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumours: a randomized trial. *Annals of Oncology*, 1992; 3: 635-638. IF 14.2
- 5 Westlin JE, **Janson ET**, Ahlström H, Nilsson S, Åkerström G, Öberg K. Scintigraphy using an 111-Indium labelled somatostatin analogue for localization of neuroendocrine tumors. *Antibody, Immunoconjugates and Radiopharmaceuticals*, 1992; Vol 5: No 4: 367-384.
- 6 **Janson ET**, Kauppinen HL, Öberg K. Combined alpha and gamma interferon therapy for malignant carcinoid tumors: a phase II trial. *Acta Oncologica*; 1993; Vol 32: No 2: 231-233. IF 3.3
- 7 **Janson ET** and Öberg K. Long-term management of the carcinoid syndrome - treatment with octreotide alone and in combination with alpha-interferon. *Acta Oncologica*, 1993; Vol 32: No 2: 225-229. IF 3.3
- 8 **Janson ET**, Westlin JE, Ahlström H, Eriksson B, Nilsson S, Åkerström G, Öberg K. Somatostatin receptor scintigraphy - recent advances imaging endocrine pancreatic tumors. *Diagnostic Oncology*, 1993; 3: 45-48.
- 9 Westlin JE, **Janson ET**, Ahlström H, Öberg K, Nilsson S. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide. *Acta Oncologica* 1993; Vol 32; No 7/8: 783-786. IF 3.3
- 10 **Janson ET**, Westlin JE, Eriksson B, Ahlström H, Nilsson S, Öberg K. [111In-DTPA-D-Phe]-octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. *Eur J of Endocrinol* 1994; 131: 577-81. IF 5.1
- 11 Sorbe B, Andersson H, Schmidt M, Söderberg M, Högberg T, Wernstedt L, **Janson ET**, Ehrnström B, Kjaer M, Havsteen H, Overgaard M, Sandberg E, Flander M, Heikkinen M, Nikkanen V. Tropisetron (Navoban) in the prevention of chemotherapy induced nausea and vomiting - the nordic experience. *Supportive Care in Cancer* 1994; 2(6): 393-396. IF 2.7
- 12 Imam H, **Janson ET**, Gobl A, Alm G, Öberg K. Induction of MxA-mRNA in patients with neuroendocrine tumors after interferon treatment - lack of correlation to antitumor response. *AntiCancer Research* 1995; 15: 2191-2196. IF 1.9

- 13 Kälkner KM, **Janson ET**, Nilsson S, Carlsson S, Öberg K, Westlin JE. Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radioligand uptake and tumor markers. *Cancer Research* 1995; 55: 5801-5804. IF 8.4
- 14 **Janson ET**, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Öberg K. Carcinoid tumors - analysis of prognostic factors and survival 301 patients from a referral center. *Annals of Oncology* 1997; 8: 685-690. IF 14.2
- 15 **Janson ET**, Gobl A, Kälkner KM, Öberg K. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. *Cancer Research* 1996; 56:2561-2565. IF 8.4
- 16 Eriksson B, **Janson ET**, Bax NDS, Mignon M, Morant R, Opolon P, Rougier P, Öberg KE. The use of new somatostatin analogs, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumors. *Digestion* 1996;57:S1:77-80. IF 3.0
- 17 Imam H, Eriksson B, Lukinius A, **Janson ET**, Lindgren PG, Wilander E, Öberg K. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. *Acta Oncologica* 1997;36:607-614. IF 3.3
- 18 Zhou Y, Gobl A, Wang S, Jacobsen MB, **Janson ET**, Haines III Gk, Radosevich JA, Öberg K. Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumours. *Eur J Cancer* 1998;34:2046-52. IF 6.7
- 19 **Janson ET**, Stridsberg M, Gobl A, Westlin JE, Öberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. *Cancer Res.* 1998 Jun 1; 58(11): 2375-2378. IF 8.4
- 20 **Janson ET**, Kälkner KM, Eriksson B, Westlin JE, Öberg K. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. *Nuclear Medicine and Biology* 1999;26:877-882. IF 2.5
- 21 **Janson ET**, Westlin JE, Öhrvall U, Öberg K, Lukinius A. Nuclear localization of ¹¹¹In after intravenous injection of [¹¹¹In-DTPA-D-Phe¹]-octreotide to patients with neuroendocrine tumors. *J Nucl Med* 2000 Sep;41(9):1514-8. IF 7.3
ABSTRACTED in the Year book of Nuclear Medicine 2001.
- 22 Skogseid B, Öberg K, Åkerström G, Eriksson B, Westlin JE, **Janson ET**, Eklöf H, Elvin A, Juhlin C, Rastad J. Limited Tumor Involvement Found at Multiple Endocrine Neoplasia Type I Pancreatic Exploration: Can It Be Predicted by Preoperative Tumor Localization? *World J Surg.* 1998 Jul; 22(7): 673-678. IF 2.8
- 23 **Janson ET**, Eriksson B, Öberg K, Skogseid B, Öhrvall U, Nilsson S, Westlin JE. Treatment with high dose Octreoscan in patients with neuroendocrine tumors - evaluation of therapeutic and toxic effects. *Acta Oncologica* 1999;38:373-377. IF 3.3
- 24 Lukinius A, Öhrvall U, Westlin JE, Öberg K and **Janson ET**. In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex. *Acta Oncologica* 1999;38:383-387. IF 3.3
- 25 Georgii-Hemming P, Strömberg T, **Janson ET**, Stridsberg M, Wiklund HJ, Nilsson K. The somatostatin analogue octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. *Blood* 1999 Mar 1;93 (5): 1724-31. IF 16.6
- 26 Cunningham JL, Lopes Egidio JR, **Janson ET**, Eriksson B, Öberg K, Gobl A. Transmembrane protein tyrosine phosphatase IA-2 (ICA 512) is expressed in human midgut carcinoids but is not detectable in normal EC cells. *J Endocrinol* 2000 Mar;164(3):315-322. IF 4.4
- 27 Portela-Gomes GM, Stridsberg M, Grimelius L, Öberg K, **Janson ET**. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. *Applied Immunohistochemistry & Molecular Morphology* 2000;8(2):126-32. IF 1.9
- 28 Afargan M, **Janson ET**, Gelerman G, Rosenfeld R, Ziv O, Karpov O, Wolf A, Bracha M, Shohat D, Liapakis G, Gilon C, Hoffman A, Stephemsky D, Öberg K. Novel long acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin. *Endocrinology*, 2001;142:477-486. IF 3.8
- 29 Fjällskog MLH, Granberg PDK, Welin LSV, Eriksson C, Öberg KE, **Janson ET**, Eriksson BK. Treatment with Cisplatin and Etoposide in Patients with Neuroendocrine Tumors. *Cancer* 2001;92:1101-1107. IF 6.1

- 30 Nilsson A., **Janson ET**, Eriksson B, Larsson A. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment. *Anticancer Research* 2001;21: 4087-4090. IF 1.9
- 31 Fjällskog ML, Sundin A, Westlin JE, Öberg K, **Janson ET**, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of a-interferon and somatostatin analogs. *Medical Oncology* 2002;19:35-42. IF 3.2
- 32 Hellman P, Lundström T, Öhrvall U, Eriksson B, Skogseid B, Öberg K, **Tiensuu Janson E**, Åkerström G. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. *World J Surgery* 2002;26(8):991-997. IF 2.8
- 33 Fjällskog ML, Ludvigsen E, Stridsberg M, Öberg K, Eriksson B, **Janson ET**. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. *Medical Oncology* 2003 Feb;20(1):59-68. IF 3.2
- 34 Fjällskog ML, Lejonklou MH, Öberg K, Eriksson B, **Janson ET**. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. *Clin Cancer Res*. 2003 Apr;9(4):1469-73. IF 8.9
- 35 Stridsberg M, Eriksson B, Öberg K, **Janson ET**. A comparison between three commercial kits for chromogranin A measurements *J Endocrinol* 2003 May;177(2):337-4. IF 4.4
- 36 Granberg D, Sundin A, **Janson ET**, Öberg K, Skogseid B, Westlin JE. Octreoscan in patients with bronchial carcinoid tumors. *Clinical Endocrinology* 2003;59:793-799. IF 2.9
- 37 Stridsberg M, Eriksson B, Öberg K, **Janson ET**. A panel of eleven region-specific radioimmunoassays for measurements of human chromogranin A. *Regulatory Peptides* 2004; 117: 219-227. IF 1.8
- 38 Ludvigsen E, Olsson R, Stridsberg M, **Janson ET**, Sandler S. Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of normal mice and rats. *J Histochemistry and Cytochemistry* 2004; 52: 391-400. IF 2.4
- 39 Welin S, **Janson ET**, Sundin A, Stridsberg M, Granberg D, Skogseid B, Öberg K, Eriksson B. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumors. *European Journal of Endocrinology* 2004; 151:107-112. IF 5.1
- 40 Tsolakis AV, Portela Gomes GM, Stridsberg M, Grimelius L, Sundin A, Eriksson B, Öberg K, **Janson ET**. Malignant gastric ghrelinoma with hyperghrelinemia. *J Clin Endocrinol Metabol* 2004; 89:3739-3744. IF 5.6
- 41 Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Öberg K, **Janson ET**. Subtype selective interactions of somatostatin and somatostatin analogues with sst₁, sst₂ and sst₅ in BON-1 cells. *Medical Oncology* 2004;21(3):285-295. IF 3.2
- 42 Stridsberg M, Eriksson B, Öberg K, **Janson ET**. A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B. *Regulatory Peptides* 2005; 125: 193-199. IF 1.8
- 43 Ludvigsen E, Stridsberg M, **Janson ET**, Sandler S. Expression of somatostatin receptor subtypes 1 - 5 in pancreatic islets of normoglycaemic and diabetic NOD mice. *European J Endocrinology* 2005;153:445-454. IF 5.1
- 44 Welin S, Fjällskog ML, Saras J, Eriksson B, **Janson ET**. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. *Neuroendocrinology* 2006;84:42-48. IF 6.8
- 45 Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Öberg K, **Janson ET**, Sandler S. Regulation of insulin and glucagon secretion by somatostatin receptor subtypes from rat pancreatic islets in vitro. *Regulatory Peptides* 2007;138:1-9. IF 1.8
- 46 Fjällskog ML, Hessman O, Eriksson B, **Janson ET**. Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. *Acta Oncologica* 2007;46:741-746. IF 3.3
- 47 Stridsberg M, Eriksson B, Fellström B, Kristjansson G, **Janson ET**. Measurements of Chromogranin B can serve as a complement to chromogranin A. *Regulatory Peptides* 2007;139:80-83. IF 1.8
- 48 Granberg D, Eriksson LG, Welin S, Kindmark, H, **Janson ET**, Skogseid B, Öberg K, Eriksson B, Nyman R. Liver embolization with trisacryl gelatin microspheres (Embosphere) in patients with neuroendocrine tumors. *Acta Radiologica* 2007;2:180-185. IF 1.6

- 49 Cunningham J, Grimelius L, Sundin A, Agarwal S, **Janson ET**. Malignant Ileocaecal Serotonin-producing Carcinoid Tumours: The presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. *Acta Oncologica* 2007;46:747-756. IF 3.3
- 50 Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, **Janson ET**, Welin S, Öberg K, Eriksson B. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. *Med Oncol.* 2007;24(3):330-7. IF 3.2
- 51 Ekeblad S, Sundin A, **Janson ET**, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Örelfors H, Sigurd M, Öberg K, Eriksson B, Skogseid B. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. *Clinical Cancer Research* 2007;13:2986-2991. IF 8.9
- 52 Saras J, Grönberg M, Stridsberg M, Öberg KE, **Janson ET**. Somatostatin induces rapid contraction of neuroendocrine cells. *FEBS Letters* 2007;581:1957-1962. IF 2.7
- 53 Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, **Janson ET**. Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas – predominance of receptor subtype 4. *Endocrine Pathology* 2007;18(2):79-85. IF 3.4
- 54 Larsson G and **Janson ET**. Anemia in patients with midgut carcinoid, treated with alpha interferon: effects by erythropoietin treatment on the perceived quality of life. *European Journal Of Cancer Care* 2008;17:200-204. IF 2.4
- 55 Tsolakis AV, Stridsberg M, Grimelius L, Portela-Gomes GM, Falkmer S, Waldum H, **Janson ET**. Ghrelin immunoreactive cells in gastric endocrine tumors and their relation to plasma ghrelin concentration. *Journal of Clinical Gastroenterology* 2008;42:381-388. IF 2.7
- 56 Fjällskog ML, **Janson ET**, Falkmer U, Vatn M, Öberg K, Eriksson B. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. *Neuroendocrinology* 2008;88:53-58. IF 6.8
- 57 Stridsberg M, Eriksson B, **Janson ET**. Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. *Regulatory Peptides* 2008;148:95-98. IF 1.8
- 58 Grönberg M, Tsolakis AV, Magnusson L, **Janson ET**, Saras J. Distribution of obestatin and ghrelin in human tissues: immunoreactive cells in the gastrointestinal tract, pancreas, and mammary glands. *J Histochem Cytochem* 2008;56:793-801. IF 2.4
- 59 Cunningham J, **Janson ET**, Agarwal S, Grimelius L, Stridsberg M. Tachykinins in endocrine tumors and the carcinoid syndrome. *Eur J Endocrinol* 2008;159:275-282. IF 5.1
- 60 Welin S, Stridsberg M, Cunningham J, Granberg D, Öberg K, Eriksson B, **Janson ET**. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. *Neuroendocrinology* 2009;89:302-307. IF 6.8
- 61 Tsolakis AV, Grimelius G, Stridsberg M, Falkmer S, Valdum H, Saras J, **Janson ET**. Obestatin/ghrelin cells in normal mucosa and endocrine tumours of the stomach. *Eur J Endocrinol.* 2009;160:941-949. IF 5.1
- 62 Kindmark H, **Janson ET**, Gustavsson B, Eriksson C, Larsson G, Granberg D, Kozlocacki G, Skogseid B, Welin S, Öberg K, Eriksson B. Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®). *Acta Oncologica* 2010;49:100-1. IF 3.3
- 63 Grönberg M, Amini RM, Stridsberg M, **Janson ET**, Saras J. Neuroendocrine markers are expressed in mammary glands. *Regulatory Peptides* 2010;160:68-74. IF 1.8
- 64 **Janson ET**, Sörbye H, Welin S, Federspiel B, Grönbäck H, Hellman P, Mathisen Ö, Mortensen J, Sundin A, Thiis-Evensen E, Välimäki M, Öberg K, Knigge U. Nordic guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. *Acta Oncologica* 2010;49:740-56. IF 3.3
- 65 Cunningham JL, Tsolakis A, Jacobson A, **Janson ET**. Connective tissue growth factor expression in endocrine tumours is associated with high stromal expression of alpha-smooth muscle actin. *Eur J Endocrinol* 2010;163:691-7. IF 5.1
- 66 Cunningham J, Diaz de Ståhl T, Sjöblom T, Westin G, Dumanski J, **Janson ET**. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. *Genes Chromosomes and Cancer* 2011;50:82-94. IF 2.9
- 67 Georgantzi K, Tsolakis AV, Stridsberg M, Jakobsson Å, Christofferson R, **Janson ET**. Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma. *Pediatric Blood and Cancer* 2011;56:584-589. IF 2.5

- 68 Walsh KM, Choi M, Öberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, **Janson ET**, Cunningham J, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J. A pilot genome-wide association study shows rare copy-number variants enriched leucocytic genome of patients with ileal neuroendocrine tumors. *Endocrine Related Cancer* 2011;18:171-180. IF 4.8
- 69 Ludvigsen E, Stridsberg M, **Janson ET**, Sandler S. Altered expression of somatostatin receptors in pancreatic islets from NOD mice cultured at different glucose concentrations in vitro and in islets transplanted to diabetic NOD mice in vivo. *Experimental Diabetes Research* 2011;2011:623472. IF 1.8
- 70 Grönberg M, Fjällskog ML, Jirstrom K, **Janson ET**. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer. *Acta Oncologica* 2012;51:386-93. IF 3.3
- 71 Norlén O, Ståhlberg P, Öberg K, Eriksson J, Hedberg J, Hessman O, **Tiensuu Janson E**, Hellman P, Åkerström G. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. *World J Surg.* 2012;36:1419-31. IF 2.8
- 72 Pazaitou-Panayiotou K, **Tiensuu Janson E**, Koletsis T, Kotoula V, Stridsberg M, Karkavelas G, Karayannopoulou G. Somatostatin receptor expression in non-medullary thyroid carcinomas. *Hormones* 2012;11:290-296. IF 1.6
- 73 Sorbye H, Welin S, Langer S, Westermark L, Holt N, Osterlund P, Dueland S, Hofslie E, Guren M, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Holst I, Federspiel B, Assmus J, **Janson ET***, Knigge U*. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. *Annals of Oncology* 2013;1:152-60. *shared last authorship. IF 14.2
- 74 Grönberg M, Tsolakis A, Holmbäck U, Stridsberg M, Grimelius L, **Janson ET**. Ghrelin and obestatin in human neuroendocrine tumors: Expression and effect on obestatin levels after meal intake. *Neuroendocrinology* 2013;97:291-9. IF 6.8
- 75 Edfeldt K, Ahmad T, Åkerström G, **Janson ET**, Hellman P, Ståhlberg P, Björklund P, Westin G. TCEB3C a putative tumor suppressor gene of small intestine neuroendocrine tumors. *Endocrine Related Cancer* 2014;21:275-284. IF 4.8
- 76 Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, Sandgren J, Diaz de Ståhl T, Zaghlool A, Giedraitis V, Lannfelt L, Score J, Cross NCP, Absher D, **Janson ET**, Lindgren CM, Morris AP, Ingelsson E, Lind L, Dumanski JP. Loss of human chromosome Y is associated with shorter survival and higher risk of cancer. *Nature Genetics* 2014; 46:624-8. IF 25.4
- 77 **Janson ET**, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, Laderkarl M, Langer SW, Mortensen J, Schalin-Jäntti C, Sundin A, Sundlöv A, Thiis-Evensen E, Knigge U. Nordic Guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. *Acta Oncologica* 2014;53:1284-97. IF 3.3
- 78 **Janson ET**. Treatment with somatostatin analogues may delay progression of neuroendocrine tumours. *Acta Oncologica* 2014;53:1283. IF 3.3
- 79 Dumanski JP, Rasi C, Lönn M, Davies H, Ingelsson M, Giedraitis V, Lannfelt L, Magnusson P, Lindgren CM, Morris AP, Cesarini D, Johannesson M, **Tiensuu Janson E**, Lind L, Pedersen NL, Ingelsson E, Forsberg LA. Mutagenesis. Smoking is associated with mosaic loss of chromosome Y. *Science* 2015;347:81-3. IF 41
- 80 Ludvigsen E, Carlsson C, **Tiensuu Janson E**, Sandler S, Stridsberg M. Somatostatin receptor 1-5; expression profiles during rat development. *Upsala Journal of Medical Sciences* 2015;120:157-68. IF 2.7
- 81 Forsberg LA, Pekar G, Rasi C, Davies H, Piotrowski A, Absher D, Ambicka A, Halaszka K, Przewoznik M, Razzaghian HR, Pakalapati S, Pasupulati S, Hacker J, Prakash KR, Lau J, Penagos-Tafurt N, Olofsson H, Hallberg G, Skotnicki P, Mitus J, Skokowski J, Jankowski M, Srucek E, Zegarski W, **Janson ET**, Rys J, Tot T, Dumanski JP. Signatures of post-zygotic structural genetic aberrations in histologically normal breast cells predisposing to development of sporadic breast cancer. *Genome research* 2015;25:1521-35. IF 9.9
- 82 Tsolakis AV, Grimelius L, Granérus G, Stridsberg M, Falkmer SE, **Janson ET**. Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours. *World Journal of Gastroenterology* 2015;21:13240-13249. IF 3.4
- 83 Haugvik SP, **Janson ET**, Österlund P, Langer SW, Falk RS, Labori KJ, Vestermark LW, Groenbaek H, Gladhaug IP, Sorbye H. Surgical treatment as a principle for patients with high-

- grade pancreatic neuroendocrine carcinoma: a Nordic multicenter comparative study. *Annals of Surgical Oncology* 2016;23:1721-8. IF 3.7
- 84 Söderquist F, **Janson ET**, Rasmusson AJ, Ali A, Stridsberg M, Cunningham JL. Melatonin immunoreactivity in malignant small intestinal neuroendocrine tumours. *PLoS One* 2016 Oct 13;11(10):e0164354. doi: 10.1371. IF 2.8
- 85 Edfeldt K, Daskalakis K, Bäcklin C, Norlén O, **Tiensuu Janson E**, Westlin G, Hellman P, Ståhlberg P. DcR3, TTF3 and Midkine are novel serum biomarkers in small intestinal neuroendocrine tumors. *Neuroendocrinology* 2017;105(2):170-181. IF 6.8
- 86 Kaltsas G, Caplin M, Davies F, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, Hörsch D, **Tiensuu Janson E**, Kiamanesh R, Kos-Kudla B, Pavel M, Rinke A, Falconi M, de Herder WW. ENETS consensus guidelines for the standard of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. *Neuroendocrinology* 2017;105(3):245-254. IF 6.8
- 87 Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Hörsch D, **Tiensuu Janson E**, Ramage J. ENETS consensus guidelines for the standards of care in neuroendocrine tumours; peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. *Neuroendocrinology* 2017;105(3):295-309. IF 6.8
- 88 Grönberg M, Ahlin C, Naeser Y, **Janson ET**, Holmberg L, Fjällskog ML. Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer. *PLoS One* 2017;12(4):e0176059. IF 2.8
- 89 Galleberg R, Knigge U, **Tiensuu Janson E**, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Gronbaek H, Österlund P, Hjortland GO, Assmus J, Tang L, Perenn A, Sorbye H. Results after surgical resection of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. *Eur J Surg Oncol* 2017;43(9):1682-1689. IF 3.4
- 90 Dumanski JP, Rasi C, Björklund P, Davies H, Ali AS, Grönberg M, Welin S, Sorbye H, Groenbaek H, Cunningham JL, Forsberg L, Lind L, Ingelsson E, Ståhlberg P, Hellman P, **Tiensuu Janson E**. A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. *Endocr Relat Cancer* 2017;24(8):427-443. IF 4.8
- 91 Ali AS, Grönberg M, Federspiel B, Soazec JY, Hjortland GO, Groenbaek H, Ladekarl M, Langer SW, Welin S, Vestermark LW, Arola J, Österlund P, Knigge U, Sorbye H, Grimelius L, **Janson ET**. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. *PLoS One* 2017;12(11):e0187667. IF 2.8
- 92 Daskalakis K, Karakatsanis A, Hessman O, Stuart HC, Welin S, **Tiensuu Janson E**, Öberg K, Hellman P, Norlén O, Ståhlberg P. Association of a prophylactic surgical approach to stage IV small intestinal neuroendocrine tumors with survival. *JAMA Oncol* 2018;4(2):183-189. IF 22.4
- 93 Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Groenbaek H, Knigge U, Sorbye H, **Janson ET**. Intravenous versus oral etoposide: Efficacy and correlation to clinical outcome in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). *Medical Oncology* 2018;35:47. IF 3.2
- 94 Georgantzi K, Sköldenberg EG, Stridsberg M, Kogner P, Jakobson Å, **Janson ET**, Christofferson RHB. Chromogranin A and neuron-specific enolase in neuroblastoma: correlation to stage and prognostic factors. *Pediatric Hematology and Oncology* 2018;35(2):156-165. IF 1.0
- 95 Grönberg M, Nilsson C, Johansson I, Hedenfalk I, Blomqvist C, Valachis A, Holmberg L, **Tiensuu Janson E**, Fjällskog ML. Ghrelin expression is associated with a favorable outcome in male breast cancer. *Scientific Reports* 2018 Sep 11;8(1):13586. doi: 10.1038/s41598-018-31783-x. IF 4.0
- 96 Toumpanakis C, Fazio N, **Tiensuu Janson E**, Hörsch D, Pascher A, Reed N, O'Toole D, Nieveen van Dijkum E, Partelli S, Rinke A, Kos-Kudla B, Costa F, Pape U, Grozinsky-Glasberg S, Scoazec JY. Unmet needs in appendiceal neuroendocrine neoplasms. *Neuroendocrinology* 2019;108(1):37-44. doi: 10.1159/000493894. IF 6.8
- 97 Georgantzi K, Sköldenberg E, **Janson ET**, Jakobson Å, Christofferson R. Diagnostic Ultrasound-guided cutting needle biopsies in neuroblastoma: a safe and efficient procedure. *Journal of Pediatric Surgery* 2019 Jun;54(6):1253-1256. IF 2.1
- 98 Georgantzi K, Tsolakakis AV, Jakobson Å, Christofferson R, **Janson ET**, Grimelius L. Synaptic vesicle protein 2 and vesicular monoamine transporter 1 and 2 are expressed in neuroblastoma. *Endocrine Pathology* 2019;30(3):173-179. IF 3.4

- 99 Dam G, Gronbaek H, Sorbye H, Thiis-Evensen E, Paulsen B, Sundin A, Jensen C, Ebbesen D, Knigge U, **Tiensuu Janson E**. Prospective study of chromogranin A as a predictor of progression in patients with pancreatic, small intestinal and unknown primary neuroendocrine tumors. Accepted for publication in *Neuroendocrinology*. IF 6.8
- 100 Lase I, Strele I, Grönberg M, Kozlovacki G, Welin S, **Janson ET**. Multiple hormone secretion may indicate worse prognosis in patients with ectopic Cushing's syndrome. Accepted for publication in *Hormones*. IF 1.6

Study Group Author

1. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmsink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. *N Engl J Med* 2012;366:2189-97.
2. Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossman A, Jense RT, Kulke M, Oeberg K, Rindi G, Sorbye H, Welin S; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. *Neuroendocrinology*. 2017;105(3):196-200. doi: 10.1159/000457956. PMID:28190015
3. Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, Kos-Kudla B, Niederle B, Nieveen van Dijkum E, O'Toole D, Pascher A, Reed N, Sundin A, Vullierme MP; Antibes Consensus Conference Participants; Antibes Consensus Conference participants. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. *Neuroendocrinology*. 2017;105(3):310-319. doi: 10.1159/000458155. Epub PMID:28222443
4. Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, Nieveen van Dijkum EJM, Pape UF, Pascher A, Ramage J, Reed N, Ruzniewski P, Scoazec JY, Toumpanakis C, Kianmanesh R, Falconi M; Antibes Consensus Conference participants. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. *Neuroendocrinology*. 2017;105(3):255-265. doi: 10.1159/000464292. PMID:28237989
5. Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O'Connor J, Sorbye H, Garcia-Carbonero R; Antibes Consensus Conference Participants; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. *Neuroendocrinology*. 2017;105(3):266-280. doi: 10.1159/000471880. PMID:28351033
6. Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O'Connor JM, O'Toole D, Rockall A, Wiedenmann B, Valle JW, Vullierme MP; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. *Neuroendocrinology*. 2017;105(3):212-244. doi: 10.1159/000471879. PMID:28355596
7. Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, O'Connor J, Eriksson B, Sorbye H, Kulke M, Chen J, Falkerby J, Costa F, de Herder W, Lombard-Bohas C, Pavel M; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. *Neuroendocrinology*. 2017;105(3):281-294. doi: 10.1159/000473892. PMID:28380493
8. Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruzniewski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D; Antibes Consensus Conference participants. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine

- Tumours: Biochemical Markers. *Neuroendocrinology*. 2017;105(3):201-211. doi: 10.1159/000472254. PMID:28391265
9. Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, Frilling A, Grossman A, Kaltsas G, Scarpa A, Welin S, Garcia-Carbonero R; ENETS 2016 Munich Advisory Board Participants. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). *Neuroendocrinology*. 2019;108(1):54-62. doi: 10.1159/000493318. PMID:30153658
 10. Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, Krenning E, O'Connor JM, Peeters M, Rindi G, Salazar R, Vullierme MP, Pavel ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. *Neuroendocrinology*. 2019;108(1):18-25. doi: 10.1159/000493319. Epub 2018 Aug 28. PMID:30153686
 11. Ramage JK, Valle JW, Nieveen van Dijkum EJM, Sundin A, Pascher A, Couvelard A, Kloepfel G; the ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. *Neuroendocrinology*. 2019;108(1):45-53. doi: 10.1159/000493767. PMID:30219817
 12. Baudin E, Hayes AR, Scoazec JY, Filosso PL, Lim E, Kaltsas G, Frilling A, Chen J, Kos-Kudła B, Gorbounova V, Wiedenmann B, Nieveen van Dijkum E, Cwikla JB, Falkerby J, Valle JW, Kulke MH, Caplin ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms. *Neuroendocrinology*. 2019;108(1):7-17. doi: 10.1159/000493980. PMID:30248673
 13. Jensen RT, Bodei L, Capdevila J, Couvelard A, Falconi M, Glasberg S, Kloppel G, Lamberts S, Peeters M, Rindi G, Rinke A, Rothmund M, Sundin A, Welin S, Fazio N; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. *Neuroendocrinology*. 2019;108(1):26-36. doi: 10.1159/000494258. PMID:30282083
 14. de Herder WW, Capdevila J; ENETS 2016 Munich Advisory Board Participants. Unmet Needs in the Field of Neuroendocrine Neoplasms of the Gastrointestinal Tract, Pancreas, and Respiratory System: Reports by the ENETS Group. *Neuroendocrinology*. 2019;108(1):5-6. doi: 10.1159/000495036. PMID:30517944

Reviews and chapters in textbooks

1. Eriksson B, **Janson ET**, Skogseid B Öberg K. Ny medicinsk behandling av neuroendokrina gastrointestinala tumörer. *Läkartidningen* 1990; 35: 2668-72.
2. Westlin JE, **Janson ET**, Ahlström H, Öhrvall U, Arnberg H, Nilsson S, Åkerström G, Öberg K. Ny diagnostisk metod. Somatostatinreceptor-scintigrafi av neuroendokrina tumörer. *Läkartidningen* 1992; 50: 4377-4379.
3. Öberg K, Eriksson B, **Janson ET**. Interferons alone or in combination with chemotherapy or other biologicals. *Digestion* 1994; 55 Suppl 3: 64-69.
4. Öberg K, Eriksson B, **Janson ET**. The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. *Molecular and Cell Biological Aspects of Gastroenteropancreatic Neuroendocrine Tumor Disease*. Eds Wiedenmann B, Kvols LK, Arnold R, Reicken EO. *Annals of the New York Academy of Sciences* 1994; 733: 471-478.
5. **Janson ET**, Öberg K. Carcinoid tumours. In: *Clinical Gastroenterology*, Eds Bloom SR, O'Shea, Bailliere's Tindall London 1996; 10:4, 589-601.
6. **Janson ET**, Öberg K. Somatostatin receptor ligands and their use in the treatment of endocrine disorders. *Curr Pharm Des*. 1999 Sep 1;5(9):693-705.
7. Öberg K, **Janson ET**, Eriksson B. Tumour markers in neuroendocrine tumours. *Ital J Gastroenterol Hepatol* 1999;31(Suppl.2):S160-2.
8. **Janson ET** and Öberg K. Malignant Neuroendocrine Tumors. *Cancer Chemotherapy and Biological Response Modifiers*, Annual 20 (Elsevier Science B.V.); Eds Giaccone G, Schilsky R and Sondel P. 2002;463-470.

9. **Janson ET** and Öberg K. Neuroendocrine Tumors –Somatostatin Receptor Expression and Somatostatin Analog Treatment. *Cancer Chemotherapy and Biological Response Modifiers*, Annual 21 (Elsevier Science B.V.); Eds Giaccone G, Schilsky R and Sondel P 2003; 535-546.
10. **Janson ET**. Carcinoid Tumors. *Oncology Review series* 2003;3:2-6.53.
11. Fjällskog ML and Janson ET. Tratamento dos tumores endócrinos do pâncreas (Treatment of endocrine pancreatic tumors) *Cancer Hoje* 2004, vol 2, no 5; 17-25.
12. Stridsberg M, **Janson ET**, Portela-Gomes GM. Cellular localisation of chromogranins and processed products in the diffuse neuroendocrine system and related tumours. In *Current Medicinal Chemistry- Immunology, Endocrine & Metabolic Agents. Hot topic issue 2004. "Chromogranin A and its derived peptides as potential regulators of immune, endocrine and metabolic systems – In search of its physiological role"* Guest Editors: Karen B. Helle and Guldborg Serck-Hanssen. Vol 4;149-160.
13. Fjällskog ML and **Janson ET**. Treatment of Endocrine pancreatic tumors. *Acta Oncologica* 2005;44:328-338.
14. **Janson ET**. Carcinoider, gastrointestinala. *Internetmedicin*, 2004, reviderad 2007.
15. **Janson ET** and Öberg K. The carcinoid syndrome. In *Gastroenterology and Hepatology: the Modern Clinician's Guide*. (Elsevier Science) Eds Weinstein WM, Hawkey CJ and Bosch J, 2005; chapter 110: pp 823-830.
16. **Janson ET** and Öberg K. Carcinoid Tumors. In *Oncology-Hematology Source Book: Evidence-Based Practice*. (McGraw Hill) Eds. Boyiadzis, Lebowitz Fojo, 2006; chapter 7: 72-79.
17. **Janson ET**. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors. *J Endocrinological Investigation* 2005; 28 (suppl to no 11):137-140.
18. Granberg D, Eriksson B, **Janson ET**, Öberg K, Skogseid B. Lungcarcinoider – inte så benigna som man trott. *Läkartidningen* 2006;34:2382-2384.
19. **Janson ET**. Treatment of neuroendocrine tumors with somatostatin analogs. *Pituitary* 2006;9:249-256.
20. Tsolakakis AV, **Janson ET**. Endocrine Pancreatic Tumors: Diagnosis and treatment. *Expert Review of Endocrinology & Metabolism* 2008;3:187-205.
21. Cunningham J, **Janson ET**. The biological hallmarks of ileal carcinoids. *Eur J Clin Invest* 2011;41:1353-1360.

Manuscripts

1. Ali AS, Grönberg M, Federspiel B, Hjortland GO, Gronbaek H, Ladekarl M, Langer SW, Welin S, Vestermark LW, Arola J, Österlund P, Knigge U, Sorbye H, Grimelius L, Micke P, **Janson ET**. Overview of PDL1 immunohistochemical expression in G3 Gastroenteropancreatic Neuroendocrine Neoplasms. (submitted)
2. Ali AS, Perren A, Lindskog C, Welin S, Sorbye H, Grönberg M, **Janson ET**. Biomarkers in Pancreatic G3 Neuroendocrine Neoplasms. (submitted)
3. Papantoniou D, Welin S, Linderholm K, **Janson ET**. Early changes of chromogranin A or 5HIAA predict for cancer specific survival and progression free survival of patients with grade 2 small intestinal neuroendocrine tumors treated with somatostatin analogues, but not PRRT (manuscript)
4. Pommergaard, HC, Nielsen K, Sorbye H, Federspiel B, Tabaksblat E, Vestermark L, **Tiensuu Janson E**, Hansen CP, Ladekarl M, Garresori H, Hjortland G, Sundlöv A, Galleberg R, Knigge P, Kjaer A, Langer SW, Knigge U. Upfront Surgery in patients with high-grade GEP-NEN and MiNEN: A Nordic multicenter study of 201 patients. (manuscript)

Invited Speaker

Invited as speaker och chair at international conferences and meetings 2-3 times per year during the last 10 year period.

2 Scientific collaboration and external research funds

I was the scientific secretary of the Nordic Neuroendocrine Tumor Group founded in 1996 from the beginning until 2004 and I am the chairman of the same group since 2004. The aim of the group is to initiate preclinical and clinical studies in the area of neuroendocrine tumors. Especially, our Nordic Registry for grade 3 neuroendocrine neoplasias has become highly recognized and rendered several publications. Our work has resulted in a new classification of these tumors, leading to better stratification for treatment for this group of patients. We have recently initiated a collaboration for grad 2 small intestinal neuroendocrine tumors and plan for further studies in the future.

Through my engagement in ENETS executive committee I am involved in several European studies concerning neuroendocrine carcinomas and appendiceal neuroendocrine tumors.

Research Grants, 2019

Swedish Cancer Society 600 000 SEK
Söderbergs fund 100 000 SEK
ALF funding 275 000 SEK

3 Thesis supervision and postgraduate education

Supervisor PhD students, graduated

Staffan Welin (2007), Janet Cunningham (2007), Apostolos Tsolakis (2008), Malin Grönberg (2010), Abir Ali (2019)

Co-supervisor PhD students, graduated

Marie-Louise Fjällskog (2002), Eva Ludvigsen (2006), Anthoula Koliadi (2014), Kleopatra Geogantzi (2018)

Supervisor PhD students, ongoing

Ieva Lase MD, Dimitrios Papantoniou MD

Other supervising assignments

Project supervisor for student in the medical program 9 times

Organizer of Postgraduate Courses

I have been course leader for compulsory courses for graduate students at the Medical Faculty, Uppsala University, 1998 - 2001. See teaching qualifications for details.

Lecturer at Postgraduate Courses

Lectures on how to prepare for the dissertation at the compulsory introduction course for graduate students at the medical faculty, Uppsala University, twice yearly 1998-2001.

Between 2001 and 2015 I gave a 2-3 hour lecture on research ethics three times every year at the compulsory introduction course for graduate students at the medical faculty, Uppsala University.

Organization of Graduate courses

As chair of the Nordic Neuroendocrine Tumor Group I have organized case-based 2 day courses for doctors treating patients with neuroendocrine tumors. Such courses have been given 5 times (the latest course 2019). Participants have been MDs from Europe.

Lecturer at Graduate Courses

I give lectures at international graduate courses regularly 3-4 times per year.

4 Other scientific qualifications

Membership in research councils and committees and other fund-awarding committees

- Scientific secretary, the Research Ethics Committee at Uppsala University 2001 - 2003.
- Substitute in the Medical and Pharmaceutical faculty's graduate studies group between 2001– 2002.
- Substitute in the working group for research ethics in medicine, the Swedish Research Council, 2002 - 2003.
- Substitute at the Central Ethical Review Board, 2004 - 2009.
- Full member of the Research and Development foundation at the National Board for Forensic Medicine, 2005-2006.
- Member of the bioethics group for the Swedish LifeGene project, 2006 - 2007.
- Member of ALF-funding priority committee, cancer, Stockholm, 2008-2010
- Member of priority committee for the Cancer foundation, Uppsala University Hospital
- Member of the funding committee at the Swedish Medical Society 2010-2012.
- Chairman of ALF-funding priority committee, cancer, Stockholm 2011-2013.
- Member of the national steering group for Biobank Sweden 2016-
- Member of the national steering group for Genomics Medicine Sweden 2017-
- Member of the national steering groups for ALF 2019-

Membership in Academies

- Member of the Swedish Society of Medicine
- Member of the Swedish Endocrine Society

- Member of the Swedish Cancer Society Network Group for Endocrine Abdominal Tumors
- Member of the Nordic Neuroendocrine Tumor Group (at present chairman)
- Member of the European Society for Clinical Investigations (ESCI) Council with special responsibility for the contacts with the associated journal, 2007 - 2010.
- Vice president European Society for Clinical Investigations 2010-2011.
- Member of the European Neuroendocrine Tumor Society (Executive committee member, asked to apply for chairman elect in March 2020)

Other Faculty Assignments

- Substitute at the Board of the Dept of Medical Sciences, Uppsala University, 2002-2005.
- Full member at the Board of the Dept of Medical Sciences, Uppsala University, 2005- 2008.

Editorial Board assignments

Member of the editorial board of European Journal of Clinical investigations
2009 – ongoing.

Reviewer for scientific journal (on a regular basis, 1-2 times per month)

Gastroenterology, Neuroendocrinology, Endocrine Related Cancer, Scandinavian Journal of Gastroenterology, Regulatory Peptides, Journal of Controlled Release, European Journal of Endocrinology, Acta Oncologica, European Journal of Clinical Investigations

Evaluator for academic positions

Senior lecturer internal medicine Karolinska Institute 2009
Promotion to professor of gastroenterology Lund University 2009
Senior lecturer in clinical science, Linköping University 2017

Faculty Opponent

Sveinung Sörhaug, 2007, Norwegian University for Science and Technology, Trondheim, Norway.

Tina Binderup, 2010, Faculty of Health Sciences, University of Copenhagen, Denmark.

David Velázquez-Fernández, 2013 Karolinska Institutet, Stockholm, Sweden.

Andreas Pfeifer, 2015, Faculty of Health Sciences, University of Copenhagen, Denmark.

Camilla B. Johnbeck, 2016, Faculty of Health Sciences, University of Copenhagen, Denmark.

Kristina BV. Dossing, 2018, Faculty of Health Sciences, University of Copenhagen, Denmark.

Tobias Hofving, 2019, Faculty of Medicine, Sahlgrenska Academy, Gothenburg University, Sweden

Member of Examination Board

Member of the examination board at dissertations or half-time evaluation >20 times.

Organizer of scientific meetings

- September 8-10, 2005 I organized an international meeting with 40 participants on neuroendocrine tumors with 25 lecturers of which 15 were from other countries in Europe and the US.
- December 8-9, 2006, I organized the "First Nordic Symposium on Neuroendocrine Tumors" in Copenhagen. The meeting was attended by 140 delegates and included 25 lecturers from the Nordic countries.
- The Harry Boström Symposium "Genetics in sporadic endocrine tumors of the gastrointestinal tract (GI-NET9). Uppsala 19 September 2008. The meeting was sponsored by the Swedish Medical Society, and attended by 50 people.
- As member of the ESCI council (European Society for Clinical Investigations) I participate in planning, evaluation of abstracts and other tasks in the preparation for the annual meetings (Geneva, March 2008, Frankfurt, 2009).
- Work-shop organizer at ESCI annual meeting in Frankfurt 2009. One and a half day on Neuroendocrine Tumors.
- I have acted as chair for the scientific committee for the "Hot Topics in NET" meeting which have been held yearly since 2015.
- I have organized the one-day symposium "Young Investigators in NET" once yearly from 2016. This symposium gives PhD students and postdocs in the neuroendocrine tumors research area the opportunity to give oral presentations of their scientific work and to net-work with colleagues in the Nordic countries.
- As member of ENETS executive committee I have participated in the organization of our Annual meeting with approximately 1500 delegates from 2016 and onwards.

National and International Prizes and Honors

- CARPA (international patient organization for carcinoid patients) prize for excellence in clinic and research, 1994.
- Lions grant-holder for excellence in cancer research at Uppsala University Hospital 2003.

Popular Science Activities

- Writing articles about neuroendocrine tumors, treatment and diagnostic procedures on several occasions for the magazine produced by the patient organization CARPA (CARPA Bulletin),

- Preparation of information material about different neuroendocrine diseases that are distributed to patients visiting our ward or out-patient clinic, example in enclosure 10.
- Participation as work-shop leader during a nation wide information day for patients with neuroendocrine tumors.
- Preparation of information material on carcinoid tumors published on the home page of the Swedish Endocrine Society.
- Teaching at patient education courses
- Participated in The Swedish Cancer Society journal discussing neuroendocrine tumors twice
- Given lectures for patients groups at their annual meetings

Management Qualifications

Formal training - courses

UGL – development of groups and leaders 15-19 November 1999.

Leadership training for female leaders 1 –8 mars 2003. Course leader Barbro Dahlbom-Hall.

Leadership program for young clinicians – Communication, leadership and development, 2001-2003 (35 days)

Kommunikation och ledarskap 2008 (3 days)

Basprogram för Chefer, Uppsala Universitet 2009-2010 (12 days)

Leadership program for women at Uppsala University 2013 (10 days)

HeLP10, Sveriges Universitets- och högskoleförbunds högre ledarprogram 2018-2019 (27 days)

Member national committees

- Biobank Sweden
- Genomics Medicine Sweden
- National ALF committee
- The governments collaboration group for Health and Life Science connected to the governments Life Science Office

Teaching Qualifications

1. Formal teaching training

- "Tutor course in Problem Based Learning" at the Dept of Medicine, 1996.
- Pedagogic course for teachers at the Medical Faculty, Uppsala University, 1996,
- "Creating WWW-pages at the Medical Faculty", Uppsala University, 1997
- " Creating WWW-pages with FrontPage/PageMill" Uppsala University, 1997.
- "IT for teachers" Uppsala University, 980305.

- "Course evaluations – how to improve our teaching" Uppsala University, 1998.
- "Pedagogic and technical use of telecommunication" autumn 1998, equal to 88 hours.
- "IT 2 – Problem based learning and IT" Uppsala University, 1999.
- "Work-Shop for construction of cases", 1 day, 2003.
- "Tutor training for the case-method", Uppsala University, 2.5 days 2004.
- "Legal aspects of education". 1 day 2005
- "Economy for university employees with administrative responsibility" 2 days 2007.

2. Experience in administration in connection with teaching

- Course director for the undergraduate course of Internal Medicine with 150 students every year 2002-2008.
- Course director for compulsory graduate courses between 1992 and 2001.
- Organizer of post-graduate course concerning neuroendocrine tumors 2003.
- Vice chairman of Stadium I (1st semester) of the New Medical Program at Uppsala University 2002-2004, see personal reflections for details.
- Member of the Analysis Group for the New Medical Program at Uppsala University, autumn 2004, see personal reflections for details.
- Chairman of Stadium II (5th-8th semesters) of the New Medical Program at Uppsala University from 2005-2011
- Member of the program committee for med Medical Program at Uppsala University since 2005-2011
- Chairman of the program committee for med Medical Program at Uppsala University 2011-2014.
- Member of the group from the Swedish National Agency for Higher Education evaluating the application from Örebro University regarding the right to start a Medical Program 2005-2006.
- Member of the group from the Swedish National Agency for Higher Education evaluating the application from Örebro University regarding the right to start a Medical Program 2007-2008.

3. Production of educational material

Editor for textbook

Redaktörer: Stefan Lindgren, Anna Engström-Laurent, Kristjan Karason, Eva Tiensuu Janson. **Medicin** (Studentlitteratur 1:a och 2:a upplagan, 2012 och 2017)

Chapters in textbooks

Janson ET and Öberg K. The carcinoid syndrome. In Gastroenterology and Hepatology: the Modern Clinician's Guide. (Elsevier Science) Eds Weinstein WM, Hawkey CJ and Bosch J, 2005; chapter 110: pp 823-830.

Janson ET and Öberg K. Carcinoid Tumors. In Oncology-Hematology Source Book: Evidence-Based Practice. (McGraw Hill) Eds. Boyiadzis, Lebowitz Fojo,

Ljunggren Ö and Tiensuu Janson E. Endokrina sjukdomar. In Medicin Eds Lindgren S, Engström-Laurent a, Karason K, Janson ET. 2012 and 2017, kapitel 10, pp593-638.

Preparation of student material

Preparation of instructions for supplementary instructors during the propedeutic course.

Clinical Qualifications

1 Clinical competence and training

University Medical Degree, Uppsala University 1988-06-10
License to practice medicine 1994-04-05
Specialist of Endocrinology and Diabetology 2001-04-24
Specialist of Internal Medicine 2002-01-10

Senior consultant at the section of endocrine oncology since 2002

2 Specialist training courses

- Nordisk kurs i diabetes, februari 1997.
- Akutmedicin, februari 1998.
- Översiktscurs i Hematologi, mars 1999.
- Stabil och instabil kranskärlssjukdom, oktober 1999.
- Nordisk kurs i hypofyses, binjurarnas och gonadernas sjukdomar, maj 2000.
- Inflammatoriska systemsjukdomar, oktober 2000.
- Nordisk kurs i tyreoida och metabola bensjukdomar, augusti 2001.

3 Other clinical assignments

- Chair Nationellt vårdprogram för gastroenteropankreatiska neuroendokrina tumörer (GEP-NET) 2015-
- Chair national quality registry for GEP-NET 2015-
- Chair working group for SVF for GEP-NET (standardiserat vårdförlopp) 2017-
- Evaluator for TLV (tand- och läkemedelsförmånsverket) 2018
- Responsible for writing an ERN-application (European Reference Network) for endocrine oncology, approved 2016